Associate Professor, Medicine, University of California, San Francisco, School of Medicine
Hematology
Dr. Phillip Febbo, MD
|
|
Give Review
Phillip Febbo is an expert in the field of Hematology. He went to medical school at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a one of the best medicals schools. University of California San Francisco School of Medicine is ranked 3/3 in Research/PrimaryCare. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Phillip Febbo is a published doctor and has 38 publications published. The lastest was: 'A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men wi...'
Publications
- A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men wi...
- A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling.
- Successful whole-exome sequencing from a prostate Cancer bone metastasis biopsy.
- Resveratrol worsens survival in SCID mice with prostate Cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.
- A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate Cancer.
- MYC activity mitigates response to rapamycin in prostate Cancer through 4EBP1-mediated inhibition of autophagy.
- Cancer gene profiling in prostate Cancer.
- MYC activity mitigates response to rapamycin in prostate Cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
- Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate Cancer: an update and review of the literature.
- Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate Cancer.
- Genomic approaches to outcome prediction in prostate Cancer.
- The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate Cancer xenograft model.
- Genomic strategy for targeting therapy in castration-resistant prostate Cancer.
- A genomic strategy to elucidate modules of oncogenic pathway signaling networks.
- Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate Cancer.
- Identification of CD15 as a marker for tumor-propagating cells in a mouse model of Medulloblastoma.
- A genomic approach to identify molecular pathways associated with chemotherapy resistance.
- NCCN Task Force Report: mTOR inhibition in solid tumors.
- Young age at diagnosis correlates with worse prognosis and defines a subset of breast Cancers with shared patterns of gene expression.
- Modeling Cancer progression via pathway dependencies.
- Stromally expressed c-Jun regulates proliferation of Prostate epithelial cells.
- Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced Cancer.
- Noise and bias in microarray analysis of tumor specimens.
- New insights into prostate Cancer biology.
- Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate Cancer.
- Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate Cancer.
- Application of a priori established gene sets to discover biologically important differential expression in microarray data.
- Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate Cancer.
- Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
- Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian Cancers.
- Androgen mediated regulation and functional implications of fkbp51 expression in prostate Cancer.
- Androgen-induced differentiation and tumorigenicity of human Prostate epithelial cells.
- mTOR inhibition reverses Akt-dependent Prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
- Use of expression analysis to predict outcome after radical Prostatectomy.
- Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate Cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioin...
- Prostate intraepithelial neoplasia induced by Prostate restricted Akt activation: the MPAKT model.
- Gene expression correlates of clinical prostate Cancer behavior.
Schools
University of California At San Francisco
Brigham and Women39s Hospital
Conditions Treated
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
University of California San Francisco School of Medicine
Hospital
-
Duke University Hospital -
UCSF Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Kelly W. Mitchell, MD |
|
|
Dr. Bradford R. Hirsch, MD |
|
|
Dr. Thomas J. Richard, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pranav D. Patel, MD |